Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation

Annals of the Rheumatic Diseases

Volumn 72, Issue 10, 2013, Pages 1680-1686

  Van Schouwenburg, Pauline A ^a   Krieckaert, Charlotte L ^b   Rispens, Theo ^a   Aarden, Lucien ^a   Wolbink, Gerrit Jan ^a,b   Wouters, Diana ^a  

^a SANQUIN RESEARCH   (Netherlands)

^b Jan Van Breemen Research Institute/Reade   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ADALIMUMAB ANTIBODY; DRUG ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY PRODUCTION; ARTICLE; DRUG BLOOD LEVEL; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOLOGICAL PROCEDURES; IMMUNOLOGICAL TOLERANCE; MAJOR CLINICAL STUDY; MALE; PH SHIFT ANTI IDIOTYPE ANTIGEN BINDING TEST; PREDICTIVE VALUE; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY FORMATION; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE;

EID: 84883822462     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202407     Document Type: Article

References (28)

1. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;8930:1105-10. (Pubitemid 24317629)
2. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor ( p75)-Fc fusion protein. N Engl J Med 1997;3:141-7. (Pubitemid 27306284)
3. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;9:1552-63. (Pubitemid 28459913)
4. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;1:35-45. (Pubitemid 36091645)
5. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;9:899-910.
6. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;7:601-8. (Pubitemid 36204954)
7. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;14:1460-8.
8. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009;5:1628-40.
9. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;3:711-15.
10. Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007;14:1391-403. (Pubitemid 47511460)
11. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;7:921-6. (Pubitemid 46999794)
12. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms. Arthritis Rheum 2009;8:2541-2.
13. Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009;68:1739-45.
14. van Kuijk AW, de GM, Stapel SO, et al. Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis 2010;3:624-5.
15. Oldenburg J, Schwaab R, Brackmann HH. Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome. Vox Sang 1999;49-54. (Pubitemid 29469258)
16. van Schouwenburg PA, Bartelds GM, Hart MH, et al. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. J Immunol Methods 2010;1- 2:82-8.
17. Smolen JS, Aletaha D. Challenges of predicting treatment response in patients with rheumatoid arthritis. Nat Clin Pract Rheumatol 2005;2:62-3.
18. Witteman AM, Stapel SO, Sjamsoedin DH, et al. Fel d 1-specific IgG antibodies induced by natural exposure have blocking activity in skin tests. Int Arch Allergy Immunol 1996;4:369-75. (Pubitemid 26082845)
19. van Schouwenburg PA, Krieckaert CL, Nurmohamed M, et al. IgG4 production against adalimumab during long term treatment of RA patients. J Clin Immunol 2012;32:1000-6.
20. Hart MH, de VH, Wouters D, et al. Differential effect of drug interference in immunogenicity assays. J Immunol Methods 2011;1-2:196-203.
21. Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol 2009;3:211-15.
22. Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006;12:3782-9. (Pubitemid 44955878)
23. Krieckaert CL, Bartelds GM, Lems WF, et al. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther 2010;5:217.
24. Hay CR, Ollier W, Pepper L, et al. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO inhibitor working party. Thromb Haemost 1997;2:234-7. (Pubitemid 27084906)
25. Oldenburg J, Picard JK, Schwaab R, et al. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997;2:238-42. (Pubitemid 27084907)
26. van Schouwenburg PA, van de Stadt LA, de Jong RN, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis 2013;72:104-9.
27. Korswagen LA, Bartelds GM, Krieckaert CL, et al. Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum 2011;4:877-83.
28. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;9285:903-11. (Pubitemid 32900579)